News

10.04.2019
 Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform фото

Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform

GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest approved product is a biosimilar monoclonal antibody, eculizumab, indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Generium is the first company in the world to develop and market a biosimilar of eculizumab.

28.03.2019
Press-release фото

Press-release

The Russian biotechnological company “Generium”, “Oxford Immunotec” and “PharmLine” agreed on the local production of the laboratory IGRA-test (Interferon gamma release assay) T-SPOT®.TB that is used for detection of tuberculosis (TB) infection. This agreement signifies a long-term cooperation in the field of high-precision diagnostic test systems for socially significant infectious diseases.